PMID: 8952558Dec 15, 1996Paper

High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma

Cancer
G D LongK G Blume

Abstract

A number of studies have demonstrated that high dose chemotherapy, with or without radiotherapy, with autologous marrow and/or peripheral blood progenitor cell support can result in improved overall and complete response rates in patients with multiple myeloma, and a minority of patients become long term survivors. Based on their favorable experience with high dose etoposide-based regimens in patients with Hodgkin's disease and non-Hodgkin's lymphoma, the authors explored the use of these regimens prior to autologous progenitor cell rescue in patients with multiple myeloma. Thirty-four patients (median age, 49 years; range, 38-65) with multiple myeloma who were responsive to standard chemotherapy were enrolled in this study. Blood progenitor cells were collected after treatment with cyclophosphamide at a dose of 4 g/m2 followed by granulocyte-colony stimulating factor (G-CSF) at a dose of approximately 10 micrograms/kg/day subcutaneously, and the collection continued daily until the target number of mononuclear cells had been obtained. The preparative regimen consisted of fractionated total body irradiation (FTBI) of 1200 centigray in 10 fractions on Day -8 to Day -5, etoposide 60 mg/kg intravenously (i.v.) on Day -4, and cyclo...Continue Reading

References

Oct 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D E ReeceC F LeMaistre
Oct 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B BarlogieF Cabanillas
Jun 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K C Anderson
Dec 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S J HorningK G Blume
Mar 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A M GianniM Boccadoro
Apr 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D CunninghamJ Malpas
Apr 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M R O'DonnellE P Smith

❮ Previous
Next ❯

Citations

Oct 8, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven N WolffF Anthony Greco
Jun 27, 2003·American Journal of Hematology·Christopher R CogleJohn R Wingard
Sep 6, 2000·Journal of Internal Medicine·G Gahrton, B Björkstrand

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.